Akebia Therapeutics (AKBA) Buy Rating Reaffirmed by Analysts at H.C. Wainwright; With $25.0000 Target; Magnegas Has 1 Sentiment

June 6, 2017 - By Darrin Black

Among 7 analysts covering Akebia Therapeutics Inc (NASDAQ:AKBA), 6 have Buy rating, 0 Sell and 1 Hold. Therefore 86% are positive. Akebia Therapeutics Inc has $26 highest and $10 lowest target. $18.20’s average target is 38.19% above currents $13.17 stock price. Akebia Therapeutics Inc had 14 analyst reports since August 13, 2015 according to SRatingsIntel. H.C. Wainwright maintained Akebia Therapeutics Inc (NASDAQ:AKBA) on Tuesday, December 15 with “Buy” rating. The stock of Akebia Therapeutics Inc (NASDAQ:AKBA) earned “Equal Weight” rating by Morgan Stanley on Thursday, August 13. The company was maintained on Wednesday, March 9 by JMP Securities. The stock of Akebia Therapeutics Inc (NASDAQ:AKBA) has “Overweight” rating given on Wednesday, September 9 by Morgan Stanley. As per Tuesday, December 15, the company rating was maintained by Needham. The rating was maintained by H.C. Wainwright with “Buy” on Tuesday, December 27. The firm earned “Neutral” rating on Thursday, January 21 by Credit Suisse. The company was maintained on Tuesday, March 15 by H.C. Wainwright. The firm has “Buy” rating given on Wednesday, September 9 by Brean Capital. As per Thursday, September 29, the company rating was initiated by Brean Capital.

MagneGas Corporation is an alternative energy company. The company has market cap of $11.55 million. The Firm creates and produces hydrogen alternative fuel through the gasification of carbon-rich liquids, including certain liquids and liquid wastes. It currently has negative earnings. The Firm is also developing the use of fuel for co-combustion with hydrocarbon fuels to reduce emissions.

About 13,380 shares traded. MagneGas Corporation (MNGA) has declined 77.22% since June 6, 2016 and is downtrending. It has underperformed by 93.92% the S&P500.

Bank Of New York Mellon Corp holds 0% of its portfolio in MagneGas Corporation for 50,901 shares. Barclays Plc owns 7,000 shares or 0% of their US portfolio. Moreover, Benjamin F. Edwards & Company Inc. has 0% invested in the company for 300 shares. The Delaware-based Blackrock Advisors Llc has invested 0% in the stock. Blackrock Fund Advisors, a California-based fund reported 8,220 shares.

Since April 3, 2017, it had 0 insider buys, and 3 selling transactions for $36,257 activity. Another trade for 991 shares valued at $9,119 was sold by Nash Duane. Shares for $12,858 were sold by Dahan Michel. The insider Hadas Nicole R. sold $14,280.

About 104,746 shares traded. Akebia Therapeutics Inc (NASDAQ:AKBA) has risen 76.80% since June 6, 2016 and is uptrending. It has outperformed by 60.10% the S&P500.

Investors sentiment increased to 1.41 in Q4 2016. Its up 0.36, from 1.05 in 2016Q3. It increased, as 5 investors sold Akebia Therapeutics Inc shares while 24 reduced holdings. 10 funds opened positions while 31 raised stakes. 19.35 million shares or 1.73% more from 19.02 million shares in 2016Q3 were reported. Trexquant L P reported 33,034 shares. Venbio Select Advisor Limited Liability Corp holds 1.75% in Akebia Therapeutics Inc (NASDAQ:AKBA) or 831,515 shares. Bnp Paribas Arbitrage, a New York-based fund reported 602 shares. Blackrock Fund stated it has 0% in Akebia Therapeutics Inc (NASDAQ:AKBA). Tower Research Limited Liability Co (Trc) has invested 0% in Akebia Therapeutics Inc (NASDAQ:AKBA). Blackrock Investment Mgmt Ltd holds 146,146 shares or 0% of its portfolio. Ellington Management Grp Lc owns 11,500 shares. Morgan Stanley stated it has 0% in Akebia Therapeutics Inc (NASDAQ:AKBA). Fmr Limited Liability has 931,855 shares. Johnson Counsel Inc reported 0.02% in Akebia Therapeutics Inc (NASDAQ:AKBA). Northern Trust owns 0% invested in Akebia Therapeutics Inc (NASDAQ:AKBA) for 365,650 shares. Tiaa Cref Invest Ltd Liability Corp accumulated 105,925 shares. Creative Planning holds 0% in Akebia Therapeutics Inc (NASDAQ:AKBA) or 10,850 shares. Acuta Cap Prtn Ltd Limited Liability Company has invested 2.71% in Akebia Therapeutics Inc (NASDAQ:AKBA). Renaissance Lc accumulated 0% or 208,600 shares.

Akebia Therapeutics, Inc. is a biopharmaceutical company. The company has market cap of $488.87 million. The Firm focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor biology. It currently has negative earnings. The Company’s lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD).